Clinical Trial

QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors

Study acronym: Spring
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 10, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
QL1706 Combined with Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors：A Single - Arm, Open - Label, Multi - Center, Prospective Phase II Clinical Trial (Spring Study)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-18; most recent amendment 2025-07-07.
Status change: Not Yet Recruiting → Recruiting 2025-07-07
Trial Details
NCT Number NCT06892925
Lead Sponsor Eastern Hepatobiliary Surgery Hospital
Conditions Biliary Tract Tumors
Enrollment 59 participants
Start Date 2025-06-14
Primary Completion 2026-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2025-07-10